NIZORAL ANTI-DANDRUFF Drug Patent Profile

Which patents cover Nizoral Anti-dandruff, and what generic alternatives are available?

Nizoral Anti-dandruff is a drug marketed by Kramer and is included in one NDA.

The generic ingredient in NIZORAL ANTI-DANDRUFF is ketoconazole. There are fifteen drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the ketoconazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nizoral Anti-dandruff

A generic version of NIZORAL ANTI-DANDRUFF was approved as ketoconazole by TARO on June 15^th, 1999.

Summary for NIZORAL ANTI-DANDRUFF

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	47
DailyMed Link:	NIZORAL ANTI-DANDRUFF at DailyMed

Pharmacology for NIZORAL ANTI-DANDRUFF

Drug Class	Azole Antifungal
Mechanism of Action	Cytochrome P450 3A4 Inhibitors Cytochrome P450 3A5 Inhibitors P-Glycoprotein Inhibitors

US Patents and Regulatory Information for NIZORAL ANTI-DANDRUFF

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kramer	NIZORAL ANTI-DANDRUFF	ketoconazole	SHAMPOO;TOPICAL	020310-001	Oct 10, 1997		OTC	Yes	Yes

Expired US Patents for NIZORAL ANTI-DANDRUFF

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Kramer	NIZORAL ANTI-DANDRUFF	ketoconazole	SHAMPOO;TOPICAL	020310-001	Oct 10, 1997
Kramer	NIZORAL ANTI-DANDRUFF	ketoconazole	SHAMPOO;TOPICAL	020310-001	Oct 10, 1997
Kramer	NIZORAL ANTI-DANDRUFF	ketoconazole	SHAMPOO;TOPICAL	020310-001	Oct 10, 1997

EU/EMA Drug Approvals for NIZORAL ANTI-DANDRUFF

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
HRA Pharma Rare Diseases	Ketoconazole HRA	ketoconazole	EMEA/H/C/003906Ketoconazole HRA is indicated for the treatment of endogenous Cushing’s syndrome in adults and adolescents above the age of 12 years.	Authorised	no	no	yes	2014-11-18

International Patents for NIZORAL ANTI-DANDRUFF

See the table below for patents covering NIZORAL ANTI-DANDRUFF around the world.

Country	Patent Number	Title	Estimated Expiration
Philippines	14635	1-(1,3-DIOKOLAN-2-YIMETHYL)-1H-IMIDAZOLES AND 1H-12,4-TRIAZOLES
Greece	62553	NOVEL 1-(1,3-DIOXALAN-2-YLMETHYL)-1H-IMIDAZOLES AND 1H-1,2,4-TRIAZOLES
Austria	187325
Finland	780294

Market Dynamics and Financial Trajectory for NIZORAL Anti-Dandruff

Last updated: January 9, 2026

Executive Summary

NIZORAL Anti-Dandruff (Active ingredient: Ketoconazole 1%) is a prominent topical antifungal treatment primarily used for managing dandruff and scalp seborrheic dermatitis. As an established over-the-counter (OTC) and prescription product, its market has experienced steady growth driven by increasing awareness of scalp health, rising incidence of dandruff, and expanding consumer preference for dermatological treatments. This report analyzes the current market forces, key drivers and restraints, competitive landscape, and forecasts its financial trajectory through 2030.

---

Market Overview

Product Profile and Regulatory Status

Attribute	Details
Active ingredient	Ketoconazole 1% (antifungal)
Formulation	Shampoo, foam, topical cream
Approval	OTC in several markets (US, EU); Prescription in others
Indications	Dandruff, seborrheic dermatitis, psoriasis

Global Market Size & Trends

Year	Market Size (USD billion)	CAGR (2021–2030)	Notes
2021	$0.8	—	Base year
2025	$1.2	8.0%	Driven by increasing dandruff prevalence
2030	$1.8	8.5%	Forecasted growth, expanded formulations

Sources: [1], [2], [3]

---

Key Market Drivers

1. Rising Awareness of Scalp Health

Consumers are increasingly recognizing dandruff as a medical concern, not merely cosmetic. Increased health literacy correlates with higher adoption of OTC anti-dandruff products like NIZORAL.

2. Growing Incidence of Dandruff Globally

The prevalence of dandruff ranges from 50% to 80% globally, influenced by factors such as humidity, climate, oily scalp, and lifestyle. Examples:

Region	Estimated Prevalence	Key Drivers
North America	~50%	Increased health awareness
Asia-Pacific	~80%	Hot, humid climate, grooming habits

Impact: Such high prevalence sustains constant demand.

3. Expanded Product Portfolio & Consumer Shift

Manufacturers now offer various NIZORAL formulations (shampoos, foams, creams), catering to diverse preferences. The rising trend toward self-care supports OTC sales growth.

4. Regulatory Approvals & Patent Lifecycles

• OTC approval: Facilitate widespread availability in North America, Europe.
• Patent expirations: Ketoconazole patents expired in many regions during 2010s, paving the way for generics that have enhanced market competition and affected pricing.

---

Market Restraints & Challenges

1. Competition from Alternative Treatments

• Active ingredients: Zinc pyrithione, selenium sulfide, coal tar, and newer antifungals such as ciclopirox.
• Impact: Market share erosion for NIZORAL in some regions.

2. Concerns Over Safety & Side Effects

• Reports of adverse effects like skin irritation and rare hepatotoxicity lead to cautious use of ketoconazole, especially oral formulations. However, topical use remains largely safe if appropriately administered.

3. Pricing Pressures & Generic Competition

Generics and private labels have dramatically reduced prices, affecting profit margins.

4. Consumer Preference Shifts

Trend toward natural or herbal remedies; some consumers view chemical-based treatments skeptically, impacting demand.

---

Competitive Landscape

Company	Key Products	Market Share	Notes
Johnson & Johnson	NIZORAL (shampoo, foam)	~30%	Market leader in several regions
GlaxoSmithKline (GSK)	Selsun Blue (selenium sulfide)	~20%	Competing antifungal
Teva, Mylan	Generic Ketoconazole products	~25%	Price-sensitive segment
Others	Natural/Herbal Alternatives	Remaining	Emerging competition

Note: Johnson & Johnson continues to dominate the anti-dandruff segment with NIZORAL.

---

Financial Trajectory and Forecast

Revenue Streams

Segment	Description	Approximate Contribution (2022)
OTC Sales	Mass-market shampoos and creams	65%
Prescription Sales	Dermatology clinics	35%

Historical Financial Data (Indicative)

Year	Revenue (USD million)	CAGR	Notes
2018	250	—	Steady growth
2020	300	8.0%	Pandemic impact minimal for OTC
2022	330	5.8%	Marginal slowdown due to generic competition

Projected Growth (2023–2030)

Year	Estimated Revenue (USD million)	Assumptions
2025	460	Continuation of CAGR ~8%
2030	700	Market expansion, new formulations, global penetration

Forecasting Basis:

• CAGR driven by increasing global markets, especially Asia-Pacific.
• Competitive pricing and new product innovations will be pivotal.
• Patent expiries, leading to increased availability of generics, are expected to reduce prices but enhance volume sales.

Factors Influencing the Trajectory

Factor	Impact	Mitigation
Patent expiries	Price reduction, higher volume	Focus on brand loyalty and product differentiation
Regulatory changes	Possible restrictions or approvals	Regulatory compliance and innovation
Consumer trends	Shift toward natural remedies	Portfolio diversification

---

Comparative Analysis: NIZORAL vs. Alternatives

Parameter	NIZORAL (Ketoconazole 1%)	Zinc Pyrithione Shampoos	Selenium Sulfide Shampoos	Natural Remedies
Efficacy	High	Moderate	Moderate	Variable
Safety	Safe, with caution	Generally safe	Mild irritation possible	Varies
Price	Premium	Moderate	Budget-friendly	Low
Market Share	~30% (Global)	Significant	Significant	Growing

---

Regulatory & Policy Considerations

• In the US, the FDA recognizes OTC ketoconazole shampoos under monograph status, facilitating widespread accessibility.
• The EU classifies ketoconazole as a medicinal product requiring prescription unless formulated as OTC.
• Stringent safety monitoring has led to scaling back of oral ketoconazole use, but topical formulations remain unaffected.

---

Key Opportunities & Strategic Recommendations

Opportunity	Strategic Action
Expansion in high-growth regions	Focus on Asia-Pacific, Africa
Product innovation	Develop herbal, low-irritant formulations
Digital marketing	Leverage e-commerce, targeted advertising
OEM & Private Label Expansion	Enter licensing agreements
Regulatory navigation	Maintain compliance, anticipate policy shifts

---

Key Takeaways

• Market growth: The global anti-dandruff market is projected to reach USD 1.8 billion by 2030, with a CAGR of approximately 8.5%.
• Consumer shifts: Rising awareness and incidence rates sustain demand, although competition and consumer preferences are evolving.
• Competitive landscape: NIZORAL maintains leadership but faces pressure from generics and natural alternatives.
• Financial outlook: Revenues are forecasted to increase significantly, driven by expanding markets and product diversification.
• Market risks: Patent expiries, safety concerns, and shifts toward natural products pose ongoing challenges.

---

FAQs

1. How does NIZORAL compare with alternative anti-dandruff treatments?

NIZORAL (ketoconazole 1%) is highly effective against fungal elements causing dandruff, with a broad safety profile. Alternatives like zinc pyrithione and selenium sulfide are effective but may vary in tolerability and consumer preference, often priced more economically.

2. What are the primary regions influencing NIZORAL's market growth?

North America and Europe are mature markets with stable growth. Asia-Pacific, Latin America, and Africa present substantial untapped opportunity due to high prevalence of dandruff and expanding consumer health awareness.

3. How have patent expiries affected the NIZORAL market?

Patent expirations during the 2010s led to an influx of generic ketoconazole products, increasing accessibility but compressing profit margins on branded formulations. This has shifted focus toward product differentiation and brand loyalty.

4. What safety concerns could impact NIZORAL’s market share?

Though topical ketoconazole is generally safe, rare cases of skin irritation and hepatotoxicity have been reported with oral use. Safety profiles remain favorable for topical formulations when used as directed.

5. What future innovations could sustain NIZORAL's market position?

Developments include herbal-based formulations, combination therapies for multifactorial scalp conditions, and advanced delivery systems to enhance efficacy and reduce side effects.

---

References

1. MarketWatch, "Global Anti-Dandruff Shampoo Market Outlook," 2022.
2. Grand View Research, "Anti-Dandruff Shampoo Market Size & Trends," 2022.
3. OECD, "Health Data & Prevalence Studies," 2021.
4. US FDA Monograph, "Topical Ketoconazole Products," 2015.
5. Johnson & Johnson Annual Report, 2022.